Evaluation of the effects of Fasting Mimicking Diet (FMD) Combined with a Low-Sugar Diet on lipid profile, glycemic, inflammatory and histologic indices in Non-Alcoholic Fatty Liver (NAFLD): a randomized control trial
- Conditions
- onalcoholic fatty liver disease.Nonalcoholic steatohepatitis (NASH)K75.81
- Registration Number
- IRCT20100524004010N31
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 75
General desire to participate in the study
Age 50-30 years
- Has evidence of non-alcoholic steatohepatitis and CAP score more than 263
Body mass index (BMI) = 25kg / m2
No history of alcohol consumption
Lack of other diseases and chronic and acute liver disorders (hepatitis B, C, etc.), biliary disease, known autoimmune diseases and hereditary disorders affecting the condition of the liver (iron, copper and ... )
No pregnancy or breastfeeding in women
Do not take hepatotoxic drugs such as phenytoin, amoxifen and lithium
Do not take antibiotics for more than a week during or before the study period
Do not consume Milk thistle(Silybum marianum)
Lack of chronic inflammatory disease
No history of cancer
Lack of treatment with anti-inflammatory drugs
Lack of recent weight loss diet
Blood pressure less than 90/160 mmHg
No kidney disease (GFR greater than 60 or creatinine between 7-1.4)
No weight loss of more than 8% in the last 6 months
Do not use weight loss drugs (chemical drugs and effective herbal products)
Changes in medications (lipid-lowering drugs, blood sugar control drugs, and blood pressure medications) during the study period
Lack of adherence to the diet given to patients
Take supplements or substances that change the individual effect of the diet during the intervention.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hepatic steatosis, Liver fibrosis. Timepoint: At the first and at the 12th week of the study. Method of measurement: fibroscan.
- Secondary Outcome Measures
Name Time Method